StoryCommercial
Boston Scientific neuromodulation sales rise 12.7% to $341M in Q2 2026
Neuromodulation, the unit that sells its spinal cord stimulators and now Nalu, grew faster than the company as a whole in the second quarter. Total revenue was $5.44B, up 7.5%.
- Neuromodulation sales: $341M, up 12.7% reported and 12.2% organic.
- Company revenue: $5.442B, 7.0% organic growth.